Background: MicroRNA (miR)-182 is frequently upregulated in cancers, has generally been viewed as an oncogene and is possibly connected to angiogenesis. We aimed to explore what impact miR-182 has in non-small cell lung cancer (NSCLC), and more explicitly its correlation with angiogenic markers.Methods: From 335 unselected stage I to IIIA NSCLC carcinomas, duplicate tumor and tumor-associated stromal cores were collected in tissue microarray blocks (TMAs). In situ hybridization (ISH) was used to detect the expression of miR-182 in tumor cells, and immunohistochemistry (IHC) was used to detect the expression of angiogenesis related protein markers.Results: In univariate analyses, high tumor cell expression of miR-182 was a positive prognostic factor for patients with squamous cell carcinoma (SCC, P = 0.042) and stage II patients (P = 0.003). Also in the multivariate analysis, high tumor cell miR-182 expression was associated with a good prognosis in the same groups (SCC: HR 0.57, CI 95% 0.33-0.99, P = 0.048; stage II: HR 0.50, CI 95% 0.28-0.90, P = 0.020). We found significant correlations between miR-182 and the angiogenesis related markers FGF2, HIF2α and MMP-7.Conclusion: In patients with SCC and in stage II patients, high tumor cell miR-182 expression is an independent positive prognostic factor. © 2014 Stenvold et al.; licensee BioMed Central Ltd.
CITATION STYLE
Stenvold, H., Donnem, T., Andersen, S., Al-Saad, S., Busund, L. T., & Bremnes, R. M. (2014). Stage and tissue-specific prognostic impact of miR-182 in NSCLC. BMC Cancer, 14(1). https://doi.org/10.1186/1471-2407-14-138
Mendeley helps you to discover research relevant for your work.